Emerging Companies

ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology. The company was formed...

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo.   The...

OncoOne: targeting oxidized MIF for solid tumors

A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma...

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK...

Twelve Bio: Building a plug-and-play CRISPR platform with Cas12a variants

Danish newco Twelve Bio is building a CRISPR-Cas12a toolbox comprising a suite of Cas12a variants that are more efficient, precise and safe to use than the wild type Cas12a enzyme for both diagnostic and therapeutic...

Kira: depleting activated dendritic cells

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...

AiCure: harnessing AI to boost adherence

AiCure is combining a decade’s worth of research into real-world patient behavior with an artificial intelligence platform to optimize patient adherence to treatments in clinical trials. Lack of patient compliance to long-term treatments can lead...

Lava: better safety for bispecifics with γδ T cell engagement

Lava’s bispecific mAbs targeting γδ T cells could match the potency of other T cell engaging technologies while offering a larger therapeutic window. The company joins a growing group of biotechs focused on γδ T...

WindMIL: T cell source is key

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens than CAR therapies engineered with peripheral blood T cells. The...

Montis: Exploring an untouched macrophage subset in immuno-oncology

Montis launched with €8.4 million and a concept that puts an immuno-oncology spin on the tumor vasculature, marking the second company seeded by oncology-focused Droia Ventures in as many weeks. Droia, which teamed up with...

C. Light opens retinal window to neurological disease

UC Berkeley spinout C. Light thinks its retina tracking technology could capture early signs of neurological diseases and variability across different patients. “We’re looking to change neurology from a reactionary area of medicine to a...

Pneumagen: out-competing viral sugar binding to prevent infection

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer. Both viruses and bacteria can interact with...

Volastra raises $12M seed led by Polaris to shut down metastasis

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...

Serentrix: pain relief without side effects

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects. Early clinical testing by Serentrix LLC has shown that the...

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...